Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


John Rother

John Rother is president and CEO of the National Coalition on Health Care

Recent stories

  • The EpiPen pricing gouging saga is the latest example of market failureSubscription

    15 SEP 2016

    The most recent example of pharmaceutical price gouging in the United States to catch public attention involves the EpiPen (adrenaline/epinephrine), a widely used injectable pen that can be life saving for those with severe allergic reactions to certain substances. The price of this device has been steadily raised by Mylan Pharmaceuticals by more than 500% since 2009, to a list price of US$609 recently. Credible estimates of actual production costs are US$30. Many parents buy these dev

  • Time for government action on unreasonable drug price hikesSubscription

    24 SEP 2015

    Many readers would have read about the outrageous price hike of the drug Daraprim (pyrimethamine) in the United States, which was acquired in August 2015 by Turing Pharmaceuticals. The price was then promptly raised to US$750 a tablet from US$13.50, bringing the annual cost of treatment for some patients to hundreds of thousands of dollars. This latest drug pricing outrage illustrates the lack of social responsibility among some companies. Another drug, cycloserine, acquired by Rodelis

  • The pharmaceutical industry have, in recent years, focused on development of so-called specialty drugs and have priced them aggressively

    New effective medicines are of no use if they are unaffordableSubscription

    9 SEP 2015

    In the United States, a campaign has been fighting for transparency in the pricing of specialty drugs.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.